BioPharmX Corp.Find Ratings Reports
BIOPHARMX CORP's gross profit margin for the first quarter of its fiscal year 2019 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased.
At the same time, stockholders' equity ("net worth") has significantly decreased by 82.69% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY19||Q1 FY18|
|Net Sales ($mil)||0.0||0.02|
|Net Income ($mil)||-3.62||-4.4|
|Balance Sheet||Q1 FY19||Q1 FY18|
|Cash & Equiv. ($mil)||3.28||10.93|
|Total Assets ($mil)||4.93||11.44|
|Total Debt ($mil)||1.22||0.0|
|Profitability||Q1 FY19||Q1 FY18|
|Gross Profit Margin||0.0||-24150.0|
|Return on Assets||-334.25||-136.78|
|Return on Equity||-1157.23||-190.16|
|Debt||Q1 FY19||Q1 FY18|
|Share Data||Q1 FY19||Q1 FY18|
|Shares outstanding (mil)||10.48||7.66|
|Div / share||0.0||0.0|
|Book value / share||0.14||1.07|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3148595.0||8009850.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 3.90 indicates a premium versus the S&P 500 average of 3.44 and a significant discount versus the industry average of 10.04. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, BIOPHARMX CORP seems to be trading at a premium to investment alternatives.
|BPMX NM||Peers 26.36||BPMX NM||Peers 32.40|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BPMX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BPMX's P/CF is negative making the measure meaningless.
|BPMX NM||Peers 15.25||BPMX NA||Peers 3.61|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BPMX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BPMX 3.90||Peers 10.04||BPMX 49.87||Peers 346.35|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BPMX is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BPMX is expected to significantly trail its peers on the basis of its earnings growth rate.
|BPMX 138.86||Peers 8.91||BPMX -45.84||Peers 8.06|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BPMX is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BPMX significantly trails its peers on the basis of sales growth.